About US
Contact us
-
Purdue and Shionogi's new constipation approval goes up against AZ, Valeant rivalsAstraZeneca’s Movantik and Valeant’s Relistor have been battling it out in the opioid-induced constipation arena since winning their FDA approvals back in September2014. Now there’s a third competitor2017/3/30
-
Pfizer, Merck KGaA score watershed FDA nod on cancer immunotherapy BavencioPfizer and Merck KGaA are officially fourth to market with their checkpoint inhibitor avelumab—but first with approval to target a rare, aggressive form of skin cancer, Merkel cell carcinoma. Now bra2017/3/29
-
It's not just lower U.S. drug prices Trump wants. He wants the lowest, periodPresident Donald Trump is back with more drug-pricing promises. This time, he says he's aiming to push prices lower than anywhere else in the world. Speaking at a meeting with members of the Congress2017/3/29
-
FDA's orphan drug program under GAO scrutiny after senators allege abuseJust weeks after senators raised questions about the FDA's orphan drug program—and after Marathon Pharmaceuticals caught fire for an $89,000 list price on an old-turned-new orphan med—the GAO has agre2017/3/28
-
FDA signs off on Parkinson's add-on drug XadagoAn add-on Parkinson’s med already available in various countries in Europe will soon make its way to the U.S. as the FDA on Tuesday approved Newron Pharmaceuticals’ Xadago. Xadago earned the FDA thum2017/3/28
-
China proposes new FDA rules to speed up foreign drug approvalsChina's FDApublished(Chinese) a slate of suggested amendments to its foreign drug registration rules Friday, whichcould dramatically revamp the country’s pharmaceutical market landscape by eliminating2017/3/27
-
J&J chief Gorsky, in China for official summit, straddles Trump's globalism divideAmid uncertainty for pharma as President Donald Trump embarks on his quest of putting “America First,” Johnson & Johnson CEO Alex Gorsky played down the potential falloutfor his company during a C2017/3/27
-
Pierre Fabre and H-Immune to develop new cancer immunotherapiesFrench pharmaceutical company Pierre Fabre and H-Immune have entered a strategic research partnership to develop new cancer immunotherapies. The partnership will use H-Immune’s In Vitro Immunization2017/3/24
-
Emergent signs $100m BARDA contract to deliver BioThraxUS-based Emergent BioSolutions has signed a $100m contract with the Biomedical Advanced Research and Development Authority (BARDA) to deliver BioThrax (Anthrax Vaccine Adsorbed) to the Strategic Natio2017/3/24
-
PCC acquires Intrathecal Therapy business from Mallinckrodt for $203mPiramal’s wholly owned Critical Care subsidiary in the UK PCC has completed its previously announced acquisition of Intrathecal Therapy business from Mallinckrodt for $203m. PCC is engaged in the fie2017/3/23